Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 131.42% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 222.58% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 40.25% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 68.3% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 222.58% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 390.88% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 152.45% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 222.58% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 390.88% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 222.58% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 110.38% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 166.48% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 54.28% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 348.81% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 334.78% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 222.58% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 320.76% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 208.56% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 180.5% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 250.63% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 208.56% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 180.5% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 236.61% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 250.63% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 236.61% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 264.66% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 222.58% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 236.61% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 390.88% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 348.81% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 362.83% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 348.81% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 264.66% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 208.56% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 334.78% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 236.61% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 194.53% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 145.44% | DA Davidson | $16 → $17.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/10/2023 | 131.42% | DA Davidson | 35 美元 → 16.5 美元 | 维护 | 购买 |
| 08/08/2023 | 222.58% | 基准 | → 23 美元 | 重申 | 购买 → 购买 |
| 06/21/2023 | 40.25% | Stifel | 17 美元 → 10 美元 | 降级 | 买入 → 持有 |
| 05/26/2023 | 68.3% | 摩根大通 | 13 美元 → 12 美元 | 维护 | 中立 |
| 05/18/2023 | 222.58% | 基准 | → 23 美元 | 重申 | 购买 → 购买 |
| 05/11/2023 | 390.88% | DA Davidson | → 35 美元 | 重申 | → 购买 |
| 03/28/2023 | 152.45% | Canaccord Genu | → 18 美元 | 重申 | → 购买 |
| 03/20/2023 | — | Exane BNP Paribas | 升级 | 表现不佳 → 中性 | |
| 03/14/2023 | 222.58% | 基准 | → 23 美元 | 重申 | → 购买 |
| 03/01/2023 | 390.88% | DA Davidson | 32 美元 → 35 美元 | 维护 | 购买 |
| 02/28/2023 | 222.58% | 基准 | → 23 美元 | 重申 | → 购买 |
| 02/16/2023 | 110.38% | Cowen & Co. | 20 美元 → 15 美元 | 维护 | 跑赢大盘 |
| 2022 年 11 月 23 日 | 166.48% | 高盛 | 22 美元 → 19 美元 | 维护 | 购买 |
| 11/09/2022 | 54.28% | 摩根大通 | 22 美元 → 11 美元 | 降级 | 超重 → 中性 |
| 11/09/2022 | 348.81% | DA Davidson | 31 美元 → 32 美元 | 维护 | 购买 |
| 2022 年 9 月 28 日 | 334.78% | DA Davidson | 30 美元 → 31 美元 | 维护 | 购买 |
| 2022 年 9 月 16 日 | 222.58% | 派珀·桑德勒 | 20 美元 → 23 美元 | 维护 | 超重 |
| 2022 年 9 月 16 日 | 320.76% | DA Davidson | 25 美元 → 30 美元 | 维护 | 购买 |
| 08/16/2022 | 208.56% | 高盛 | 25 美元 → 22 美元 | 维护 | 购买 |
| 08/10/2022 | 180.5% | 派珀·桑德勒 | 22 美元 → 20 美元 | 维护 | 超重 |
| 08/10/2022 | 250.63% | DA Davidson | 24 美元 → 25 美元 | 维护 | 购买 |
| 07/08/2022 | 208.56% | 派珀·桑德勒 | 24 美元 → 22 美元 | 维护 | 超重 |
| 06/30/2022 | 180.5% | Canaccord Genu | 22 美元 → 20 美元 | 维护 | 购买 |
| 2022 年 12 月 5 日 | 236.61% | DA Davidson | 35 美元 → 24 美元 | 维护 | 购买 |
| 05/11/2022 | 250.63% | 高盛 | 29 美元 → 25 美元 | 维护 | 购买 |
| 05/11/2022 | 236.61% | 派珀·桑德勒 | 26 美元 → 24 美元 | 维护 | 超重 |
| 04/28/2022 | 264.66% | 派珀·桑德勒 | 31 美元 → 26 美元 | 维护 | 超重 |
| 03/14/2022 | 222.58% | 基准 | 18 美元 → 23 美元 | 维护 | 购买 |
| 03/11/2022 | 236.61% | 摩根大通 | → 24 美元 | 启动覆盖开启 | → 超重 |
| 2022 年 2 月 23 日 | 390.88% | DA Davidson | 32 美元 → 35 美元 | 维护 | 购买 |
| 2022 年 7 月 1 日 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 | |
| 12/23/2021 | — | 雷蒙德·詹姆 | 启动覆盖开启 | → 市场表现 | |
| 11/10/2021 | 348.81% | DA Davidson | 26 美元 → 32 美元 | 维护 | 购买 |
| 2021 年 8 月 10 日 | 362.83% | Stifel | → 33 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 4 月 10 日 | 348.81% | Cowen & Co. | → 32 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 08/11/2021 | 264.66% | DA Davidson | 17.5 美元 → 26 美元 | 维护 | 购买 |
| 07/19/2021 | 208.56% | 杰富瑞 | → 22 美元 | 启动覆盖开启 | → 购买 |
| 07/01/2021 | 334.78% | 高盛 | → 31 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 6 月 24 日 | 236.61% | 派珀·桑德勒 | → 24 美元 | 启动覆盖开启 | → 超重 |
| 06/15/2021 | 194.53% | Canaccord Genu | → 21 美元 | 启动覆盖开启 | → 购买 |
| 06/01/2021 | 145.44% | DA Davidson | 16 美元 → 17.5 美元 | 维护 | 购买 |
What is the target price for Beauty Health (SKIN)?
Beauty Health（SKIN）的目标价格是多少？
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by DA Davidson on August 10, 2023. The analyst firm set a price target for $16.50 expecting SKIN to rise to within 12 months (a possible 131.42% upside). 19 analyst firms have reported ratings in the last year.
DA Davidson于2023年8月10日公布了Beauty Health（纳斯达克股票代码：SKIN）的最新目标股价。这家分析公司将目标股价定为16.50美元，预计SKIN将在12个月内升至16.50美元（可能上涨131.42％）。去年有19家分析公司公布了评级。
What is the most recent analyst rating for Beauty Health (SKIN)?
分析师对美容健康（SKIN）的最新评级是多少？
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by DA Davidson, and Beauty Health maintained their buy rating.
Beauty Health（纳斯达克股票代码：SKIN）的最新分析师评级由DA Davidson提供，Beauty Health维持买入评级。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
Beauty Health（SKIN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Beauty Health的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Beauty Health 的最新评级是在2023年8月10日提交的，因此您应该预计下一个评级将在2024年8月10日左右公布。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析师对美容健康 (SKIN) 的评级是否正确？
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a maintained with a price target of $35.00 to $16.50. The current price Beauty Health (SKIN) is trading at is $7.13, which is out of the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Beauty Health（SKIN）评级维持不变，目标股价为35.00美元至16.50美元。Beauty Health（SKIN）目前的交易价格为7.13美元，超出了分析师的预测区间。